Chemicals & Small Molecules

Zinlirvimab is a humanized IgG1-λ2 monoclonal antibody that neutralizes HIV by targeting the HIV-1 gp120 envelope glycoprotein, specifically the IIIB gp120 V3 loop [1] [2].

Alunacedase alfa (APN-01) is a soluble angiotensin-converting enzyme 2 (hrsACE2) with antiviral activity that reduces the competitive entry of SARS-CoV-2 into cell membranes bound to ACE2. alunacedase alfa mimics ACE2 in vivo and can be used to study novel coronavirus infections, pulmonary hypertension and acute lung injury. Alunacedase alfa mimics ACE2 in vivo and can be used to study novel coronavirus infections, pulmonary hypertension and acute lung injury.

Bintrafusp alfa (M7824) is a bifunctional fusion protein consisting of the extracellular structural domain of TGF-βRII (a TGF-β “trap”) fused to a monoclonal antibody against human immunoglobulin G1 fused to programmed death ligand 1 (PD-L1), which is known for its anticancer activity, and can be used to study esophageal cancer. It has anticancer activity and can be used to study esophageal cancer.

BEBT-109 is a potent selective inhibitor of pan-mutant EGFR with enhanced pharmacokinetic properties, suitable for research on various mutant-EGFR-driven non-small cell lung cancer (NSCLC) [1].

TCRS-417 (T417), a small molecule compound, selectively binds to the interface between PBX1 and its specific DNA target sequence, disrupting the PBX1-DNA interaction. This compound has potential research applications in cancer, developmental, inflammatory, autoimmune, and neurodegenerative diseases [1].

Peimisine 3-O-β-D-glucopyranoside is a steroidal alkaloid isolated from the bulb of Monocarpus monocarpus with partial neuroprotective activity, and can be used for the study of rotenone-induced neurotoxicity in the PC12 cell line.

Obexelimab (XmAb5871) is a bifunctional monoclonal antibody that binds CD19 and FcyRIIb, inhibits B-cells, plasmoblasts, and plasma cells, and may be used in the study of autoimmune diseases such as systemic lupus erythematosus.

Marstacimab (PF-06741086) is a neutralizing antibody that binds to and inhibits inhibitors of the human tissue factor pathway. Marstacimab is an anti-tissue factor pathway inhibitor used in the study of hemophilia.

Hydrogenated soya phosphatidylcholines, a natural compound, enhances the controlled release of water-soluble drugs in oral drug delivery systems by improving drug loading and solubility [1].